ADAMIS PHARMACEUTICALS CORP(NASDAQ:ADMP) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to ADMP. ADMP was compared to 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ADMP have multiple concerns. ADMP does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

ADMP had negative earnings in the past year.

ADMP had a negative operating cash flow in the past year.

In the past 5 years ADMP always reported negative net income.

In the past 5 years ADMP always reported negative operating cash flow.

1.2 Ratios

ADMP has negative profitability rations, so we won't be analyzing them here.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ADMP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ADMP does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ADMP has about the same amount of shares outstanding.

ADMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ADMP has an Altman-Z score of -115.24. This is a bad value and indicates that ADMP is not financially healthy and even has some risk of bankruptcy.

ADMP's Altman-Z score of -115.24 is on the low side compared to the rest of the industry. ADMP is outperformed by 97.60% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-115.24

ROIC/WACCN/A

WACC8.93%

2.3 Liquidity

ADMP has a Current Ratio of 0.23. This is a bad value and indicates that ADMP is not financially healthy enough and could expect problems in meeting its short term obligations.

ADMP's Current ratio of 0.23 is on the low side compared to the rest of the industry. ADMP is outperformed by 94.71% of its industry peers.

ADMP has a Quick Ratio of 0.23. This is a bad value and indicates that ADMP is not financially healthy enough and could expect problems in meeting its short term obligations.

The Quick ratio of ADMP (0.19) is worse than 95.19% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.23
Quick Ratio	0.19

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ADMP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.47%, which is quite impressive.

The Revenue has grown by 700.00% in the past year. This is a very strong growth!

ADMP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.29% yearly.

EPS 1Y (TTM)40.47%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%14.18%

Revenue 1Y (TTM)700%

Revenue growth 3Y-40.07%

Revenue growth 5Y-18.29%

Sales Q2Q%120%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADMP. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ADMP!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ADAMIS PHARMACEUTICALS CORP

NASDAQ:ADMP (9/7/2023, 8:00:00 PM)

After market: 0.77 -0.01 (-0.66%)

0.7751

+0.01 (+0.86%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-08 2023-08-08/amc

Earnings (Next)11-13 2023-11-13/amc

Inst Owners0%

Inst Owner Change-93.33%

Ins Owners95.51%

Ins Owner Change0%

Market Cap2.16M

Analysts43.33

Price Target0.43 (-44.52%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.42
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-11.03

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-4.83

FCFYN/A

OCF(TTM)-4.72

OCFYN/A

SpS1.84

BVpS-4.12

TBVpS-4.12

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover1.08

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	30.93%
Cap/Sales	5.86%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.23
Quick Ratio	0.19
Altman-Z	-115.24

F-Score4

WACC8.93%

ROIC/WACCN/A

Cap/Depr(3y)52.33%

Cap/Depr(5y)73.76%

Cap/Sales(3y)34.55%

Cap/Sales(5y)28.02%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)40.47%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%14.18%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)700%

Revenue growth 3Y-40.07%

Revenue growth 5Y-18.29%

Sales Q2Q%120%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y22.11%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y60.09%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y59.92%

OCF growth 3YN/A

OCF growth 5YN/A

ADAMIS PHARMACEUTICALS CORP (ADMP) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens